Medindia

X

Amarin Provides 2009 Year-End Review to Shareholders

Thursday, January 28, 2010 Corporate News J E 4
Advertisement
New investors and experienced new team focused on driving Phase 3 clinical development of AMR101 for cardiovascular diseases

Contacts:

Investor Contact Information:

John F. Thero

Chief Financial Officer

In US: +1 (860) 572 4979

investor.relations@amarincorp.com

Gitanjali Ogawa

The Trout Group

In U.S. +1 (646) 378-2949

gogawa@troutgroup.com

International Media Contact Information:

Mark Swallow or David Dible

Citigate Dewe Rogerson

In UK: +44 (0)207 638 9571

mark.swallow@citigatedr.co.uk

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Japan Science and Technology Agency (JST) Selects ...
S
Merck Receives European Approval for ELONVA(R) (co...